Ants, spiders, and mold: Why a big compounding pharmacy recently recalled all its products (STAT)
In the wake of patient death, Sutro says its Chinese partner is rethinking their deal and withholding $40M (Endpoints)
Sanofi, Regeneron build their case for yet another approval for immunology star Dupixent (Endpoints)
As Eli Lilly steams ahead with a closely-watched BTK drug, its rivals at Merck are taking a $275M write-down on delay (Endpoints)
Pfizer and Alvotech look to interchangeability to stand out in a crowded Humira biosimilar field (Endpoints)
Emergent's troubled Baltimore site gets $100M upgrade (Endpoints)
Medtech
FDA's performance against MDUFA IV decision goal falls to new low (MedTech Dive)
European Regulatory Roundup February 2022: Major Push Now On IVD Regulation Preparedness (MedTech Insight)
Medtech, hospitals on alert for cyberattacks after Russia's invasion of Ukraine (MedTech Dive)
FDA Stresses Need For Routine Monitoring Of Endovascular Aortic Repair Patients (MedTech Insight)
Boston Scientific touts early results of real-world Watchman FLX study (MedTech Dive)
Government, Regulatory & Legal
Endo Held Liable in Opioid Case Via Default Judgment (Bloomberg)
Diabetes Drugmakers Seek Judgment After Plaintiffs’ Expert Axed (Bloomberg)
Eli Lilly Whistleblower Advances Medicaid Drug Suit Toward Trial (Bloomberg)
Justices Probe Proof Burden in ‘Pill Mill’ Prosecutions (Bloomberg)
HHS sets out plans to make medical device, diagnostics supply chains pandemic-proof (MedTech Dive)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
BARCELONA – A panel of experts at the RAPS AI in Regulatory Conference discussed how artificial intelligence (AI) is being used by a wide range of stakeholders, including notified bodies and healthcare product manufacturers.